The story of Viagra presents a intricate picture for shareholders. While the initial launch generated massive gains, the end of its patent opened the floodgates to off-brand versions, dramatically eroding revenue. This https://bookmarkzap.com/story21521309/the-copyright-and-big-pharma-a-risky-opportunity